MMED Stock Overview
A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Mind Medicine (MindMed) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.90 |
| 52 Week High | US$16.40 |
| 52 Week Low | US$3.30 |
| Beta | 2.39 |
| 1 Month Change | 0% |
| 3 Month Change | 0.81% |
| 1 Year Change | 200.40% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 145.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| MMED | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 1.9% |
| 1Y | 200.4% | -55.0% | 10.7% |
Return vs Industry: MMED exceeded the Canadian Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: MMED exceeded the Canadian Market which returned 10.7% over the past year.
Price Volatility
| MMED volatility | |
|---|---|
| MMED Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.3% |
Stable Share Price: MMED has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MMED's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Rob Barrow | www.mindmed.co |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Mind Medicine (MindMed) Inc. Fundamentals Summary
| MMED fundamental statistics | |
|---|---|
| Market cap | CA$693.64m |
| Earnings (TTM) | -CA$170.82m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs MMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMED income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$125.32m |
| Earnings | -US$125.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.2% |
How did MMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/07 21:45 |
| End of Day Share Price | 2024/04/10 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mind Medicine (MindMed) Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |